Literature DB >> 11050474

Transduction of a fiber-mutant adenovirus for the HSVtk gene highly augments the cytopathic effect towards gliomas.

N Shinoura1, S Sakurai, A Asai, T Kirino, H Hamada.   

Abstract

Suicide gene therapy utilizing the herpes simplex thymidine kinase (HSVtk) / ganciclovir (GCV) system has been performed to kill cancer cells. However, the low transduction efficiency of HSVtk gene into cancer cells critically limits its efficacy in cancer treatment in clinical situations. To improve delivery of the HSVtk gene into cancer cells, we transduced U-87MG and U-373MG glioma cells with adenovirus (Adv) vectors with a fiber mutant, F / K20, which has a stretch of 20 lysine residues added at the C-terminus of the fiber, for the HSVtk gene (Adv-TK-F / K20), and compared the cytopathic effect of Adv-TK-F / K20 with that of the Adv for HSVtk with wild-type fiber (Adv-TK). The cytopathic effect of Adv-TK-F / K20 in U-87MG and U-373MG cells was approximately 140 and 40 times, respectively, stronger than that of Adv-TK. At the same multiplicity of infection (MOI) in each cell line, Adv-TK-F / K20 induced a higher degree of apoptosis (U-87MG, 35%; U-373MG, 77%) than Adv-TK (U-87MG, 0.11%; U-373MG, 27%) in U-87MG (MOI 0.03) and U-373MG cells (MOI 0.1). Cleavage of poly(ADP-ribose)polymerase (PARP) was more marked in the cells that were infected with Adv-TK-F / K20 than in cells that were infected with Adv-TK. These results indicate that gene therapy utilizing Adv-TK-F / K20 may be a promising therapeutic modality for the treatment of gliomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050474      PMCID: PMC5926260          DOI: 10.1111/j.1349-7006.2000.tb00881.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  19 in total

1.  Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases.

Authors:  C Beltinger; S Fulda; T Kammertoens; E Meyer; W Uckert; K M Debatin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas.

Authors:  N Shinoura; Y Yoshida; R Tsunoda; M Ohashi; W Zhang; A Asai; T Kirino; H Hamada
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

3.  Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

Authors:  Z Ram; K W Culver; E M Oshiro; J J Viola; H L DeVroom; E Otto; Z Long; Y Chiang; G J McGarrity; L M Muul; D Katz; R M Blaese; E H Oldfield
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

4.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

5.  Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma.

Authors:  Y Yoshida; A Sadata; W Zhang; K Saito; N Shinoura; H Hamada
Journal:  Hum Gene Ther       Date:  1998-11-20       Impact factor: 5.695

6.  Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.

Authors:  E H Oldfield; Z Ram; K W Culver; R M Blaese; H L DeVroom; W F Anderson
Journal:  Hum Gene Ther       Date:  1993-02       Impact factor: 5.695

7.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

8.  A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.

Authors:  M Schuler; C Rochlitz; J A Horowitz; J Schlegel; A P Perruchoud; F Kommoss; C T Bolliger; H U Kauczor; P Dalquen; M A Fritz; S Swanson; R Herrmann; C Huber
Journal:  Hum Gene Ther       Date:  1998-09-20       Impact factor: 5.695

9.  Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy.

Authors:  N Shinoura; Y Yoshida; A Sadata; K I Hanada; S Yamamoto; T Kirino; A Asai; H Hamada
Journal:  Hum Gene Ther       Date:  1998-09-20       Impact factor: 5.695

10.  Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells.

Authors:  Y Miyao; K Shimizu; M Tamura; H Akita; K Ikeda; E Mabuchi; H Kishima; T Hayakawa; K Ikenaka
Journal:  Jpn J Cancer Res       Date:  1997-07
View more
  2 in total

Review 1.  Gene therapy for high-grade glioma: current approaches and future directions.

Authors:  Atsushi Natsume; Jun Yoshida
Journal:  Cell Adh Migr       Date:  2008-07-13       Impact factor: 3.405

2.  Tumor necrosis factor alpha-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors.

Authors:  Yuka Okada; Naoki Okada; Shinsaku Nakagawa; Hiroyuki Mizuguchi; Koichi Takahashi; Nobuyasu Mizuno; Takuya Fujita; Akira Yamamoto; Takao Hayakawa; Tadanori Mayumi
Journal:  Jpn J Cancer Res       Date:  2002-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.